![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
S Akiyama, MM Cornwell, M Kuwano, I Pastan and MM Gottesman
Department of Cancer Chemotherapy, Faculty of Medicine, Kagoshima University, Japan.
Multidrug-resistant human KB carcinoma cells express a 170,000-dalton membrane glycoprotein (P-glycoprotein) that can be photoaffinity labeled with the vinblastine analog N-(p-azido-[3-125I]salicyl]-N'- (beta-aminoethyl)vindesine. Several agents that suppress the multidrug- resistant phenotype, including N-solanesyl-N,N'-bis(3,4- dimethylbenzyl)ethylenediamine, cepharanthine, quinidine, and reserpine, were found to inhibit photolabeling of P-glycoprotein at doses comparable to those that reverse multidrug resistance. However, the phenothiazines chlorpromazine and trifluoperazine, which also effectively reverse multidrug resistance, were poor inhibitors of the photoaffinity labeling of P-glycoprotein. Chloroquine, propranolol, or atropine, which only partially reversed the drug resistance, also did not inhibit photolabeling. Naphthalene sulfonamide calmodulin inhibitors, W7 and W5, as well as many other drugs that did not circumvent multidrug resistance, did not inhibit photolabeling. These studies suggest that most, but not all, agents that phenotypically suppress multidrug resistance also inhibit drug binding to a site on P- glycoprotein with which a photoaffinity analog of vinblastine interacts.
This article has been cited by other articles:
|
|
 |
|
  J. Hoffmann, I. Vitale, B. Buchmann, L. Galluzzi, W. Schwede, L. Senovilla, W. Skuballa, S. Vivet, R. B. Lichtner, J. M. Vicencio, et al. Improved Cellular Pharmacokinetics and Pharmacodynamics Underlie the Wide Anticancer Activity of Sagopilone Cancer Res., July 1, 2008; 68(13): 5301 - 5308. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Leveque and F. Jehl Molecular Pharmacokinetics of Catharanthus (Vinca) Alkaloids J. Clin. Pharmacol., May 1, 2007; 47(5): 579 - 588. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Sarkadi, L. Homolya, G. Szakacs, and A. Varadi Human Multidrug Resistance ABCB and ABCG Transporters: Participation in a Chemoimmunity Defense System. Physiol Rev, October 1, 2006; 86(4): 1179 - 1236. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Okumura, Z.-S. Chen, M. Sakou, T. Sumizawa, T. Furukawa, M. Komatsu, R. Ikeda, H. Suzuki, K. Hirota, T. Aikou, et al. Reversal of P-Glycoprotein and Multidrug-Resistance Protein-Mediated Drug Resistance in KB Cells by 5-O-Benzoylated Taxinine K Mol. Pharmacol., April 13, 2001; 58(6): 1563 - 1569. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. W. Loo and D. M. Clarke Blockage of Drug Resistance In Vitro by Disulfiram, a Drug Used to Treat Alcoholism J Natl Cancer Inst, June 7, 2000; 92(11): 898 - 902. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Sumizawa, Z.-S. Chen, Y. Chuman, K. Seto, T. Furukawa, M. Haraguchi, A. Tani, N. Shudo, and S.-I. Akiyama Reversal of Multidrug Resistance-Associated Protein-Mediated Drug Resistance by the Pyridine Analog PAK-104P Mol. Pharmacol., March 1, 1997; 51(3): 399 - 405. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
